Genmab announced a pharma deal with Eli Lilly and Company to use and evaluate Genmab’s DuoBody technology platform for the creation of bispecific antibodies.
Lilly will initially evaluate the DuoBody technology platform in house.
The financial terms of the agreement have not been disclosed.
This agreement will not have a material impact on Genmab’s financial results and cash position.
View the full article at Genmab website.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Eli Lilly
Report: Partnering Deals and Alliances with Genmab
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity